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ABSTRACT  
 
Objectives: We examined the influence of choice of endpoint on trial size, duration and interpretation 
of results in patients with heart failure enrolled in the Beta-blocker Evaluation of Survival Trial 
(BEST).  
Background:  The choice of endpoints in heart failure trials has evolved over the last decades. 
Methods: In the BEST trial we examined the effect of bucindolol on the now standard composite of 
cardiovascular death or heart failure hospitalization (CVD/HFH), compared with the original primary 
mortality endpoint, and the expanded composite including emergency department (ED) visits using 
Cox regression analysis. We also undertook an analysis of recurrent events primarily using Lin, Wei, 
Ying and Yang model. 
Results:  Overall, 448 (33%) placebo patients and 411 (30%) bucindolol patients died (HR 0.90; 95% 
CI 0.78-1.02; p=0.11). 730 (54%) patients experienced CVD/HFH on placebo and 624 (46%) on 
bucindolol (0.80; 0.72-0.89; p<0.001). Adding ED visits increased these numbers to 768 (57%) and 
668 (49%), respectively (0.81; 0.73-0.90; p<0.001). 568 (42%) placebo patients experienced HFH 
compared with 476 (35%) bucindolol patients (0.78; 0.69-0.89; p <0.001) with a total of 1333 and 
1124 admissions, respectively. With the same statistical assumptions, using the composite endpoint 
instead of all-cause mortality would have reduced the trial size by 40% and follow-up duration by 
69%. The rate ratio for recurrent events (CVD/HFH) was 0.83 (0.73-0.94), p=0.003. 
Conclusion:  Choice of endpoint has major implications for trial size and duration, as well as 
interpretation of results. The value of broader composite endpoints and inclusion of recurrent events 
needs further investigation. 
 
Keywords: heart failure, BEST, endpoint, recurrent events 
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Abbreviations and acronyms:   
BEST = Beta-blocker Evaluation of Survival Trial 
CI =confidence interval 
CV =cardiovascular 
ED =emergency department 
HF =heart failure 
HR =hazard ratio 
LVEF=left ventricular ejection fraction 
NYHA =New York Heart Association 
WLW =Wei, Lin and Weissfeld  
LWYY =Lin, Wei, Ying and Yang 
 
  
5 
 
INTRODUCTION 
The choice of endpoints in heart failure (HF) trials has evolved over the past three decades. Initially, 
death from any cause was commonly used as the primary endpoint but with incremental 
improvements in therapy it has become more common to use mortality-morbidity composite 
outcomes (1-3). In part, these reflect improving survival in HF and the resultant feasibility and 
affordability of conducting mortality trials. However, incorporation of hospital admissions for HF 
in composites also recognizes the importance of these non-fatal events to the overall burden of HF 
and their economic significance (4-6). More recently, cardiovascular (CV) rather than all-cause 
mortality has been incorporated in composite outcomes. This recognizes the likely absence of effect 
of novel treatments for HF on non-cardiovascular death and the growing proportion of deaths 
attributable to non-cardiovascular causes because of the cumulative benefits of effective treatments 
on cardiovascular mortality (7-9). Similarly, with improving survival and chronicity of HF, it has 
been suggested that analysis of all events, including repeat events, better reflects the overall burden 
of the condition than the conventional time-to-first event analysis (10-14). Most recently, clinical 
practice has evolved, particularly in the United States, to attempt to manage episodes of HF 
worsening without formal admission to hospital. This potentially means that HF hospitalization may 
no longer reflect the true extent of treatment failure. Consequently, it has been suggested that these 
non-hospitalized episodes should be included in composite outcomes (5,15,16). However, there are 
few data on the frequency of occurrence of these and whether or not they respond to study treatment 
in the same way as hospital admission.  
 
We used the Beta-blocker Evaluation of Survival Trial (BEST) to examine the implications of this 
evolution in trial endpoints in heart failure with reduced ejection fraction (HF-REF) (17,18). BEST 
is of particular interest because information of emergency department (ED) visits, as well as HF 
hospitalizations, was collected systematically during the trial. 
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METHODS 
Study design and patients 
BEST was a randomized double-blind trial of bucindolol in patients with HF, funded by the National 
Heart, Lung, and Blood Institute (NHLBI) and the Department of Veterans Affairs (17,18). The BEST 
protocol and results have been published. In brief, 2708 HF patients with a left ventricular ejection 
fraction (LVEF) ≤35% and New York Heart Association (NYHA) class III or IV symptoms were enrolled 
in the United States and Canada from 1995 to 1998 and randomly assigned to receive bucindolol or 
placebo. The primary endpoint was death from any cause. The secondary endpoints included CV death 
and HF hospitalization. The cause of death was adjudicated blindly by the central endpoint committee. 
The de-identified public-use copy of the BEST database provided by the NHLBI, which included all but 
one participant, was used for the current analysis.  
 
Outcomes 
HF hospitalizations and ED visits for HF were reported by investigators. Specifically, the investigator 
was asked on the hospitalization or ED visit form to state whether the visit was due to worsening HF 
(“yes” or “no”), where investigators were instructed to select “yes” only if the visit was due to 
decompensated HF. We defined an isolated ED visit for HF as one which occurred without a subsequent 
HF hospitalization within 30 days, and if patients were hospitalized within 30 days after an ED visit, they 
were classified as having a HF hospitalization. The outcomes of interest in this analysis included: the 
composite of time to first HF hospitalization or CV death; the expanded composite of time to first CV 
death, HF hospitalization or ED visit for HF; all HF hospitalizations (including repeats); and a composite 
of all HF hospitalizations and CV death (each CV death was counted as an additional event except when 
a patient died during a HF admission). 
 
Statistical analyses 
Time to first event analyses 
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The baseline characteristics of patients having first isolated ED visit for HF, HF hospitalization or CV 
death or none of these events were compared using ANOVA for continuous variables and Chi-square test 
for categorical variables. HF duration was not normally distributed and thus was compared using Kruskal-
Wallis test.  
 
The association between a first non-fatal event (ED visit for HF or HF hospitalization) and 
subsequent mortality was examined using time-updated Cox regression analysis with patients with 
neither event as the reference group. The association was adjusted for treatment assignment and 
baseline covariates including age, sex, race, systolic blood pressure, heart rate, BMI, LVEF, NYHA 
class, ischemic etiology, hypertension, diabetes, myocardial infarction, atrial fibrillation, previous 
implantable cardioverter defibrillator and serum creatinine. Treatment effect on the composite, and 
on the expanded composite and its components was examined using Cox regression analysis.  
 
Assuming all-cause mortality, the composite or the expanded composite as the endpoint, we 
examined the time taken to accrue a certain number of the assumed events, and also examined the 
sample size required to detect 20% reduction in the assumed endpoint with bucindolol therapy using 
log-rank test assuming a two-sided significant level of 5%, statistical power of 85%, equal 
allocation, 3-year uniform accrual period, a minimum follow-up of 1 year and a maximum follow-
up of 4 years. 
 
Recurrent events analysis 
Recurrent events are commonly analyzed using count data methods, e.g. negative binomial regression, 
and using time-to-event data methods, e.g. Andersen-Gill, Wei, Lin and Weissfeld (WLW), and Lin, Wei, 
Ying and Yang (LWYY) models, all of which are extensions of Cox proportional hazards regression (10-
13). There is debate about which of these approaches is best to use and some considerations around this 
debate are outlined in the Supplement. As in the present study, the event rate and treatment effect were 
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not constant during follow-up, which violate the assumption of negative binomial regression; therefore, 
the LWYY model was used as the primary method and the negative binomial and WLW regressions as 
sensitivity analyses. 
 
We calculated the HF hospitalization rate by treatment group by dividing the total number of HF 
hospitalizations by the total number of follow-up years in each group. The cumulative rates of HF 
hospitalizations over time by treatment group were plotted using the non-parametric Ghosh and Lin 
method, accounting for the competing risk of death. Treatment effect on all HF hospitalizations and on 
the composite of all HF hospitalizations and CV death was analyzed primarily using the LWYY model, 
and additionally using the negative binomial and WLW regressions. Given the inconstant treatment effect 
on HF hospitalization over time, sensitivity analyses were performed by assessing the treatment effects 
within 6 months and beyond 6 months since randomization. To account for the association between HF 
hospitalization and subsequent mortality and the competing risk of mortality on HF hospitalizations, the 
joint frailty model was used to analyze recurrent HF hospitalizations and time to CV death 
simultaneously.   
 
A two-sided p value <0.05 was considered significant. The recurrent event analysis was undertaken using 
R (version 3.2.3). All other analyses were performed using the Stata version 14 (College Station, TX, 
USA).  
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RESULTS 
Of the 2707 patients analyzed, 1353 were randomized to placebo and 1354 to bucindolol. The median 
duration of follow-up was 2.0 years.  
 
Deaths:   Overall, 448 patients (33%) assigned to placebo and 411 (30%) assigned to bucindolol 
died with a hazard ratio (HR) in the bucindolol group of 0.90 (95% CI: 0.78 to 1.02; p=0.11). The 
number in each treatment group who died from a CV cause was 388 (29%) and 342 (25%) 
respectively (HR, 0.86; 95% CI: 0.75 to 1.00; p=0.045).  
 
Hospital admissions for HF: Overall, 568 patients (42%) assigned to placebo and 476 (35%) 
assigned to bucindolol had a HF hospitalization (HR 0.78; 95% CI, 0.69 to 0.89; p <0.001). There 
was a total of 1333 admissions in the placebo group and 1124 in the bucindolol group (Table 1). 
 
ED visits for HF:   A total of 334 placebo treated patients (25%) had an ED visit for HF; this 
number was 281 (21%) in the bucindolol group, HR 0.81 (95% CI 0.69 to 0.95), p=0.01. Of these, 
161 (11.9% of all patients) and 138 (10.2%) patients, respectively, were not admitted to hospital 
(48% and 49% of patients, respectively, presenting to the ED were not admitted), HR 0.84 (95% CI 
0.67 to 1.06), p =0.14. Overall, there were 586 ED visits for HF in the placebo group and 510 in the 
bucindolol group. Of these, 211 (36% of visits) and 176 (35%) respectively did not result in a 
proximate hospital admission (Table 1). 
 
Characteristics of patients with an adverse outcome:   The baseline characteristics of patients 
experiencing a CV death, HF hospitalization or ED visit for HF (or none of these) are shown in 
Table 2. Overall patients who died had more characteristics associated with worse outcome (e.g. 
older age, lower blood pressure, estimated glomerular filtration rate and LVEF, ischemic etiology, 
NYHA class IV) and those who had no event had the least of these characteristics. Patients with HF 
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hospitalization and ED visits were in-between these two extremes, although patients with ED visits 
appeared less sick, overall, compared with those hospitalized. 
 
Association between HF worsening and subsequent mortality:   Compared to patients not 
experiencing an ED visit (or HF hospitalization), those with an ED visit for HF were subsequently 
twice as likely to die during follow-up (HR, 2.05; 95% CI: 1.47 to 2.84; p <0.001), even after 
adjustment for other prognostic variables, HR 1.90 (1.37 to 2.65), p <0.001. In similar analyses, 
patients hospitalized for worsening HF were four times as likely to die; unadjusted HR 4.65 (4.02 to 
5.37), adjusted HR 3.72 (3.20 to 4.33), both p <0.001. 
 
  
Composite clinical outcomes:   The number of patients experiencing the composite of first HF 
hospitalization or CV death was 730 (54%) and 624 (46%) in the placebo and bucindolol groups, 
respectively; HR 0.80 (95% CI 0.72 to 0.89), p <0.001. Adding ED visits for HF increased the 
numbers of patients affected to 768 (57%) and 668 (49%), respectively; HR 0.81 (0.73 to 0.90), 
p<0.001 (Figure 1). 
 
Implications for trial size and duration:   The number of days taken to accrue 500 patients with a 
death from any cause was 515, for the composite of HF hospitalization or CV death this figure was 
162 days and for the expanded composite including ED visits it was 136 days. There was a 
substantial decrease in the sample size when using the composite outcomes. For example, with a 
power of 85% to detect 20% reduction in the bucindolol group at a significant level of 5%, the 
sample size was 2454 for death from any cause, 1524 for the composite and 1432 for the composite 
including ED visits. 
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Recurrent HF hospitalizations:  There were a total of 1333 HF hospitalizations in the placebo 
group and 1124 in the bucindolol group, including 765 (57.4% of all admissions) and 648 (57.7%) 
repeated admissions, respectively. The frequencies of HF hospitalizations by treatment group were 
presented in Table 1. Over 25% of all HF admissions occurred within 6 months of randomization, 
and the figure was 25.2% (n=336) in the placebo group and 29.3% (n=329) in the bucindolol group 
(Supplement Figure A).  
 
The HF hospitalization rates were 49.5 and 40.8 per 100 patient-years in the placebo and bucindolol 
groups, respectively. Compared to the placebo group, the cumulative rate in the bucindolol group 
was lower after 6 months, although before 6 months it was slightly higher, i.e. the cumulative event 
curves “crossed-over” at about 6 months. The corresponding cumulative rate ratio (bucindolol vs. 
placebo) appeared to remain constant at approximately 0.83 after 6 months (Figure 2).  
 
Patients having at least one HF hospitalization were more likely to have baseline characteristics 
associated with worse outcomes (Supplement Table A).  
 
For all HF hospitalizations, the LWYY regression model gave an overall HR for bucindolol of 0.82 
(95% CI 0.71 to 0.95, p=0.008). A similar estimate was observed from the WLW model (0.80, 0.68 
to 0.94, p=0.005), while a smaller and non-significant effect was obtained from negative binomial 
and joint frailty models (both gave a rate ratio of 0.89, with 95% CI 0.77 to 1.04) (Table 3). 
However, when separate estimations were made for the first 6 months and the remainder of follow-
up, the results were consistent across different methods. Based on the LWYY model, the estimate 
was 0.98 (95% CI 0.80 to 1.21, p=0.88) within 6 months and 0.77 (0.65 to 0.91, p=0.002) after 6 
months. Nearly identical estimates were observed for the composite of all HF hospitalizations and 
CV death from the corresponding regression models (Table 3). 
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DISCUSSION 
The purpose of this study was to illustrate the implications of the choice of primary endpoint in 
clinical trials in HF-REF and how this choice has evolved (and continues to evolve) in recent years.  
Perhaps the most striking conclusion is that, had the primary endpoint most commonly used in 
recent HF trials been used in BEST, the trial would have clearly been “positive” instead of “neutral” 
or “negative” as it is historically regarded. This difference reflects two things. Firstly, the much 
larger number of events in the composite outcome (1354 versus 859 deaths) and the fact that 129 
deaths were non-cardiovascular. While a larger number of events, per se, does not increase 
statistical power, HF hospitalizations are events likely to be favourably influenced by an effective 
therapy and therefore did increase power. Conversely, a beta-blocker was unlikely to decrease the 
risk of non-cardiovascular death meaning that the 15% of deaths that were not cardiovascular 
effectively diluted the benefit of bucindolol on the original primary endpoint (by adding “noise”). 
As a result, switching from an all-cause mortality endpoint to the composite of CV death or HF 
hospitalization would have had a dramatic impact on sample size in BEST – assuming the same 
treatment effect-size, power and significance level (20%, 85% and 5%, respectively), the sample 
size would have been reduced by nearly 40% (from n=2454 to 1524) and the time taken to accrue a 
requisite number of endpoints (e.g. n=500) reduced by an even greater amount (515 to 162 days, a 
69% reduction).  
 
While we found bucindolol reduced the composite of CV death or HF hospitalization, a broader 
composite including ED visits, and recurrent events, it did not reduce all-cause mortality, as 
demonstrated with three other beta-blockers (19). The reason for this remains uncertain although the 
specific pharmacologic properties of bucindolol, the racial mix of the population studied in BEST 
and interactions between the two have been implicated (20,21).  
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Despite a benefit of bucindolol on the composite of CV death or HF hospitalization, an early 
increase in HF hospitalization was observed among patients treated with bucindolol. HF worsening 
is a recognized risk early after initiation of beta-blocker treatment and is thought to be minimized 
by starting with a low-dose of treatment. This finding was also seen in the Metoprolol CR/XL 
Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) although apparently not in 
the Carvedilol Prospective Randomized Cumulative Survival trial (COPERNICUS) which also 
enrolled patients with more severe HF, as in BEST (the relevant analysis has not been reported for 
the second Cardiac Insufficiency Bisoprolol Study, CIBIS-2) (22-24). However, the dose up-
titration rate in BEST was more rapid (weekly) than in the other trials (two-weekly in 
COPERNICUS and MERIT-HF; weekly to 5mg in CIBIS-2 and then four-weekly). Another 
possible reason could be the potent sympatholytic effect of bucindolol. Another analysis of BEST 
showed that a decrease in plasma norepinephrine levels after 3 months of treatment was associated 
with higher risk of death or HF hospitalization in the bucindolol group (25). 
 
Because of changing practice, it has been suggested that composite outcomes be further expanded 
to include episodes of HF worsening that do not lead to formal hospital admission (5,15,16,26,27). 
BEST was unusual in systematically documenting ED visits. Although not as numerous as HF 
hospitalizations, ED visits were common. However, most were associated with a hospital admission 
shortly thereafter. Consequently, in a time to first event analysis, isolated ED visits added relatively 
few unique events (5%). Nevertheless, these were enough to shorten the time to accrual of a target 
number of events (as used in an event-driven trial) by around 15%. There may be concerns about 
inclusion of ED visits in the composite outcome (5,15,16,26,27). Firstly, these events may not 
reflect worsening of HF in the same way as hospitalization either because the events may be less 
severe or because patient evaluation during an ED visit may be less comprehensive than during a 
hospital admission and diagnosis less certain. For these reasons, ED visits may also be less 
responsive to the experimental treatment (especially if there is mis-diagnosis).  Nevertheless, 
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scrutiny of the characteristic of patients with ED visits showed they had features associated with 
worse outcomes, although less advanced than in patients who were hospitalized or died. In keeping 
with this, patients with an ED visit in BEST were subsequently twice as likely to die compared to 
those without an ED visit (or hospitalization for HF), confirming the findings of another more 
recent trial and some epidemiological data (16,27); patients hospitalized with worsening HF were 
four times as likely to die. The effect of bucindolol on ED visits was similar to that on CV death 
and on HF hospitalization. Consequently, including ED visits in the composite outcome would not 
only have reduced the study size (from 1524 to 1432 in the scenario outlined above) and shortened 
the time to accrual of a target number of events (e.g. from 162 to 132 days for 500 events) but 
would also have slightly narrowed the 95% CIs around the point estimate for the effect of 
bucindolol. 
 
As survival has increased, HF has become a more chronic condition with recurrent non-fatal 
hospitalizations an increasingly important reflection of the overall burden of the disease on patients 
and health care systems alike. This has led to the suggestion that analysis of all events, including 
repeat hospital admissions, may provide a better evaluation of the effect of treatment than time-to-
first event analysis which has been the conventional approach used to estimate treatment-effect in 
clinical trials (5,11-15). A variety of statistical approaches can be employed to do such analyses and 
there has been discussion about which of these is best to use. We found the two most commonly 
advocated approaches (i.e. negative binomial and joint frailty models) showed somewhat less 
favourable treatment effects than the WLW model and LWYY model (the principal method in this 
study). This may result from the violation of two important assumptions of negative binomial 
regression in BEST, i.e. the constant event rate and the constant treatment effect over time. This 
was also the case for the joint frailty model which is in effect a combination of negative binomial 
regression for recurrent HF hospitalizations and Cox regression for time to CV death. The rate of 
HF hospitalizations was relatively high early after randomization (i.e. over the first 6 months) and 
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lower thereafter. As mentioned above, bucindolol treatment led to an early increase in risk of HF 
hospitalization followed by a later decrease. When estimations were made separately within 6 
months and beyond 6 months, fairly consistent results were observed using the different modelling 
approaches.  
 
Interestingly, the proportional reduction in risk estimated using all of these methods was smaller 
than obtained in conventional time-to-first event analysis. The reason for this observation is 
uncertain but may reflect the early increase in hospitalization following initiation of bucindolol 
before the longer-term reduction in recurrent events with this treatment became evident. If correct, 
and whatever the reason, these findings highlight the need to better understand the effect of 
therapies on recurrent events and how analyses of these might be used in future clinical trials. 
 
As with all studies, there are limitations. Firstly, this was a post hoc analysis. Secondly, it has been 
argued that the actions of bucindolol may be unique among the beta-blockers tested in large 
outcome trials although the benefits observed in BEST were generally in keeping with those seen in 
the other trials (20,28). Thirdly, there was potential violation of proportional hazards assumption for 
the Cox models in the composite and the expanded composite outcome analyses, given the cross-
over in the Kaplan-Meier curves, although the Schoenfeld residuals test was not significant for 
either (both p value >0.05). Lastly, we only used investigator reported HF hospitalizations and ED 
visits in our analyses; however, a previous analysis showed a similar treatment effect of bucindolol 
on first hospitalizations for HF when adjudicated events were used instead (29). 
 
In summary, choice of endpoint has major implications for trial size and duration, as well as 
interpretation of results. The use of broader composite endpoints that include non-hospitalized 
manifestations of HF worsening may further reduce sample size and trial length. However, the role 
of additional manifestations of worsening other than ED visits needs further study. Similarly, the 
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potential role of analysis of recurrent events as a trial endpoint needs further investigation. This type 
of analysis may not give the same estimate of treatment effect as time-to-first event analysis, 
although the level of agreement may differ for different treatment. This finding does, however, raise 
the interesting question as to which approach, time-to-first event analysis or analysis of all (first and 
recurrent) events, gives the more clinically relevant answer? 
 
 
 
 
 
Clinical Perspectives  
The choice of primary endpoints has major influence on trial size and duration and on the 
interpretation of results. The use of broader composite endpoints including ED visits for HF 
worsening may further reduce trial size and length.  
 
Translational Outlook 
Further studies are required to determine the values of broader composite endpoints and inclusion of 
recurrent events, and to standardize the approach for the analysis of recurrent events if included as 
endpoints. 
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FIGURE LEGEND 
Figure 1 Kaplan-Meier curves for composite outcome (A) and the expanded composite 
outcome (B) according to treatment group. 
 
Figure 2 Estimated cumulative rate of heart failure hospitalizations per 100 patients over time 
by treatment group and the corresponding risk ratio (bucindolol versus placebo) for 
the cumulative rate of heart failure hospitalizations. 
 
TABLE LEGEND 
Table 1 Number of heart failure hospitalizations and emergency department visits for heart 
failure by treatment group in BEST. 
 
Table 2 Baseline characteristics of patients with first emergency department visit for heart 
failure, heart failure hospitalization, or neither, or experiencing cardiovascular death. 
 
Table 3 Treatment effects (bucindolol versus placebo) on all heart failure hospitalizations 
(first and recurrent) and the composite of all heart failure hospitalizations and 
cardiovascular deaths using different methods to analyse recurrent events. 
 
 
SUPPLEMENT 
Discussion of approaches to analysis of recurrent events. 
Supplement Table A Baseline characteristics according to the number of heart failure 
hospitalizations. 
Supplement Figure A Distribution of time from randomization to any heart failure 
hospitalization by treatment group. 
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Table 1 Number of heart failure hospitalizations and emergency department visits for heart 
failure by treatment group in BEST. 
 
  Placebo Bucindolol 
Number of patients 1353 1354 
Total years of follow-up 2694 2755 
Number of deaths 448 411 
Number of CV deaths 388 342 
HF hospitalization   
Patients with ≥1 hospitalization 568 476 
Patients with ≥2 hospitalizations 323 246 
Number of HF hospitalizations 1333 1124 
Patients with number of hospitalizations   
1 245 230 
2 152 97 
3 74 61 
4 32 27 
5 27 24 
6 17 13 
7 7 9 
8 4 4 
9 2 4 
10 3  3 
11 0  1 
12 3  1 
13 0  1 
14 0  1 
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16 2  0 
ED visit for HF   
Patients with ≥1 ED visit  334 281 
Patients with ≥2 ED visits 122 97 
Number of ED visits  586 510 
Isolated ED visit for HF   
Patients with ≥1 isolated ED visit 161 138 
Patients with ≥2 isolated ED visits  31 25 
Number of isolated ED visits  211 176 
 
CV denotes cardiovascular; ED, emergency department; HF, heart failure. 
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Table 2 Baseline characteristics of patients with first emergency department visit for heart failure, heart failure hospitalization, or neither, or 
experiencing cardiovascular death. 
  No relevant event ED visit for HF HF hospitalization CV death p value 
n (%) 1271 (47.0) 199 (7.4) 986 (36.4) 251 (9.3)  
Age -year 59.1±12.4 59.6 ±12.2 61.2±12.3 62.8±11.9 <0.001 
Male sex -n (%) 982 (77.3) 155 (77.9) 776 (78.7) 201 (80.1) 0.727 
Race -n (%)     0.055 
White 911 (71.7) 133 (66.8) 662 (67.1) 189 (75.3)   
Black 274 (21.6) 48 (24.1) 256 (26.0) 49 (19.5)   
Hispanic 67 (5.3) 11 (5.5) 56 (5.7) 9 (3.6)   
Other 19 (1.5) 7 (3.5) 12 (1.2) 4 (1.6)   
Blood pressure -mmHg      
Systolic 119.5±17.9 116.7±18.5 114.5±17.8 115.7±17.9 <0.001 
Diastolic 72.3±11.2 71.8±11.8 69.9±10.9 68.8±11.1 <0.001 
Heart rate -beats/min 81.4±13.0 81.2±13.9 82.1±13.4 81.1±12.8 0.566 
BMI - kg/m2 28.3±6.0 29.1±6.4 27.5±5.7 27.1±5.4 <0.001 
HF duration* -months 30 [10-64] 39 [10-72] 41 [16-75] 46 [13-78] <0.001 
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Left ventricular ejection fraction -% 24.4±7.0 23.0±7.1 21.7±7.3 21.6±7.1 <0.001 
NYHA class -n (%)     <0.001 
III 1208 (95.0) 184 (92.5) 869 (88.1) 220 (87.7)  
IV 63 (5.0) 15 (7.5) 117 (11.9) 31 (12.4)  
Ischemic etiology -n (%) 672 (52.9) 111 (55.8) 623 (63.2) 181 (72.1) <0.001 
Medical history -n (%)      
Myocardial infarction 485 (38.2) 75 (37.7) 452 (45.8) 132 (52.6) <0.001 
Angina 618 (48.6) 107 (53.8) 535 (54.3) 140 (55.8) 0.024 
CABG 331 (26.0) 60 (30.2) 303 (30.7) 88 (35.1) 0.010 
PCI 189 (14.9) 35 (17.6) 161 (16.3) 38 (15.1) 0.672 
Hypertension 720 (56.6) 126 (63.3) 598 (60.6) 151 (60.2) 0.129 
Diabetes 393 (30.9) 84 (42.2) 380 (38.5) 107 (42.6) <0.001 
Atrial fibrillation 263 (20.7) 39 (19.6) 283 (28.7) 68 (27.1) <0.001 
Treatment -n (%)      
Randomized treatment 686 (54.0) 97 (48.7) 449 (45.5) 122 (48.6) 0.001 
Digitalis 1141 (89.8) 186 (93.5) 933 (94.6) 239 (95.2) <0.001 
Diuretic 1156 (91.0) 190 (95.5) 946 (95.9) 241 (96.0) <0.001 
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ACE inhibitor 1168 (91.9) 183 (92.0) 886 (89.9) 232 (92.4) 0.308 
ACE inhibitor or ARB 1241 (97.6) 195 (98.0) 942 (95.5) 239 (95.2) 0.016 
Spironolactone 35 (2.8) 4 (2.0) 43 (4.4) 10 (4.0) 0.121 
ICD 36 (2.8) 4 (2.0) 46 (4.7) 4 (1.6) 0.020 
Pacemaker 95 (7.5) 19 (9.5) 93 (9.4) 24 (9.6) 0.328 
Laboratory measures      
Serum creatinine -mg/dl 1.16±0.36 1.26±0.43 1.32±0.44 1.31±0.40 <0.001 
eGFR -ml/min/1.73m2 74.2±23.8 69.4±23.8 65.8±25.5 64.4±22.1 <0.001 
eGFR <60 ml/min/1.73m2 347 (28.1) 70 (35.5) 427 (44.4) 118 (48.0) <0.001 
 
ACE denotes angiotensin converting enzyme; ARB, angiotensin II receptor antagonist; BMI, body mass index; CABG, coronary artery bypass grafting; 
CV, cardiovascular; ED, emergency department; eGFR, estimated glomerular filtration rate; HF, heart failure; ICD, implantable cardioverter-
defibrillator; NYHA, New York Heart Association; PCI, percutaneous coronary intervention.        
*Heart failure duration is presented as median with interquartile range. 
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Table 3 Treatment effects (bucindolol versus placebo) on all heart failure hospitalizations (first and recurrent) and the composite of all heart 
failure hospitalizations and cardiovascular deaths using different methods to analyse recurrent events.   
 
Entire follow-up within 6 months beyond 6 months 
 
HR/RR (95% CI) p value HR/RR (95% CI) p value HR/RR (95% CI) p value 
Time to 1st HF hospitalization 0.78 (0.69-0.89) <0.001 0.88 (0.73-1.06) 0.190 0.72 (0.61-0.84) <0.001 
All HF hospitalizations 
      
LWYY  0.82 (0.71-0.95) 0.008 0.98 (0.80-1.21) 0.880 0.77 (0.65-0.91) 0.002 
WLW 0.80 (0.68-0.94) 0.005 0.99 (0.80-1.23) 0.940 0.74 (0.62-0.89) 0.001 
Negative binomial  0.89 (0.77-1.04) 0.137 1.00 (0.82-1.24) 0.970 0.80 (0.68-0.95) 0.010 
Joint frailty* 0.89 (0.77-1.04) 0.128 1.02 (0.82-1.27) 0.840 0.80 (0.67-0.95) 0.010 
All HF hospitalizations & CV death 
     
LWYY  0.83 (0.73-0.94) 0.003 0.97 (0.80-1.18) 0.770 0.78 (0.67-0.90) 0.001 
WLW 0.80 (0.69-0.92) 0.002 0.98 (0.80-1.19) 0.840 0.75 (0.64-0.88) <0.001 
Negative binomial  0.89 (0.78-1.01) 0.066 1.00 (0.82-1.21) 0.990 0.80 (0.69-0.93) <0.001 
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CI denotes confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; LWYY, Lin, Wei, Ying and Yang model; RR, rate ratio; WLW, 
Wei, Lin and Weissfeld model.  
*The corresponding HR for CV death in the joint frailty model was 0.93 (95% CI 0.77-1.13, p=0.47) in the entire follow-up, 1.02 (95% CI 0.72-1.44, p= 
0.91) within 6 months, and 0.86 (95% CI 0.69-1.07, p=0.17) beyond 6 months.
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Figure 1 Kaplan-Meier curves for composite outcome (A) and the expanded composite outcome (B) according to treatment group. 
 
 
CV denotes cardiovascular; ED, emergency department; HF, heart failure. 
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Figure 2 Estimated cumulative rate of heart failure hospitalizations per 100 patients over time by treatment group and the corresponding risk ratio 
(bucindolol versus placebo) for the cumulative rate of heart failure hospitalizations.       
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